Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q1 FY26 results · Apr–Jun 2025
Marksans Pharma reported revenue from operations of ₹619.99 crore (up 5.0% from Q1 FY25) and net profit of ₹58.20 crore (down 34.7% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 619.99 | 590.62 | +5.0% | 70.85 | +775.1% |
| Other income | 5.64 | 14.95 | −62.3% | 1.65 | +241.5% |
| Total income | 625.63 | 605.57 | +3.3% | 72.50 | +763.0% |
| Profit before tax | 76.60 | 120.02 | −36.2% | 11.61 | +559.8% |
| Net profit for the period | 58.20 | 89.07 | −34.7% | 9.07 | +541.5% |
| Attributable to shareholders of the company | 58.32 | 88.75 | −34.3% | — | — |
| EPS, basic (₹) | 1.29 | 1.96 | −34.2% | 2.00 | not comparable |
| Net margin (%) | 9.4 | 15.1 | 12.8 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 319.73 | 254.53 | +25.6% | 299.36 | +6.8% |
| Other income | 2.01 | 8.15 | −75.3% | 7.82 | −74.3% |
| Total income | 321.74 | 262.68 | +22.5% | 307.17 | +4.7% |
| Profit before tax | 63.57 | 42.30 | +50.3% | 49.90 | +27.4% |
| Net profit for the period | 48.06 | 32.02 | +50.1% | 37.59 | +27.8% |
| EPS, basic (₹) | 1.06 | 0.71 | +49.3% | 0.83 | +27.7% |
| Net margin (%) | 15.0 | 12.6 | 12.6 |
Consolidated
- Filed with BSE
- 12 Aug 2025, 15:08 IST
- Board meeting
- 12 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2025, 15:08 IST
- Board meeting
- 12 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE